Trials / Completed
CompletedNCT00626392
Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia
Multicenter, Randomized, Double-Blind, Parallel, Acetylsalicylic Acid (ASA) Run-In Study to Evaluate the EFFECTS of Acetylsalicylic Acid on Niaspan®-Induced Flushing in Subjects With Dyslipidemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 277 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study was to assess the effect of aspirin (ASA) on niacin extended-release (NER)-induced flushing in subjects with dyslipidemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | niacin extended-release (NER) | Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period |
| DRUG | aspirin (ASA) | 325 mg tablets administered once daily |
| DRUG | aspirin placebo (ASA Pbo) | Tablets administered once daily |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2008-02-29
- Last updated
- 2009-09-02
- Results posted
- 2009-08-25
Locations
26 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00626392. Inclusion in this directory is not an endorsement.